N2-phenylbenzo[d]oxazol-2,5-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: N2-phenylbenzo[d]oxazol-2,5-diamine
• 英文别名: 2-N-phenyl-1,3-benzoxazole-2,5-diamine
• 化学式: C₁₃H₁₁N₃O
• 分子量: 225.25
• InChiKey: INUBOKWARQSSDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N2-phenylbenzo[d]oxazol-2,5-diamine 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 羟胺 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.5h， 生成 5-((E)-4-(N'-hydroxycarbamimidoyl)phenoxy)-N-(2-(phenylamino)benzo[d]oxazol-5-yl)pentanamide
  参考文献：
  名称：

  신규한 화합물, 이의 제조방법 및 이를 포함하는 골다공증 완화, 예방 또는 치료용 약학조성물

  摘要：

  本发明提供了以下[化学式I]的新化合物，其药学上可接受的盐，或其水合物或溶剂化合物，以及其制备方法和含有效量的治疗骨质疏松症的缓解、预防或治疗组合物。[化学式I]

  公开号：

  KR101857141B1
• 作为产物：
  描述：

  N-苯基-N'-(2-羟基-5-硝基苯基)硫脲 在 potassium superoxide 、 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 N2-phenylbenzo[d]oxazol-2,5-diamine
  参考文献：
  名称：

  5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression

  摘要：

  5-Lipoxygenase synthesizes leukotrienes from arachidonic acid. We developed three novel 5-LO inhibitors having a benzoxazole scaffold as a potential anti-osteoclastogenics. They significantly suppressed RANKL-induced osteoclast formation in mouse bone marrow-derived macrophages. Furthermore, one compound, K7, inhibited the bone resorptive activity of osteoclasts. The anti-osteoclastogenic effect of K7 was mainly attributable to reduction in the expression of NFATc1, an essential transcription factor for osteoclast differentiation. K7 inhibited osteoclast formation via ERR and p38 MAPK, as well as NF-kappa B signaling pathways. K7 reduced lipopolysaccharide (LPS)-induced osteoclast formation in vivo, corroborating the in vitro data. Thus, K7 exerted an inhibitory effect on osteoclast formation in vitro and in vivo, properties that make it a potential candidate for the treatment of bone diseases associated with excessive bone resorption. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.09.025

文献信息

• 신규한 화합물, 이의 제조방법 및 이를 포함하는 골다공증 완화, 예방 또는 치료용 약학조성물
  申请人：Ewha University - Industry Collaboration Foundation 이화여자대학교 산학협력단(220040083301) BRN ▼110-82-10456

  公开号：KR101857141B1

  公开（公告）日：2018-05-14

  본 발명은 하기의 [화학식 I]의 신규한 화합물, 이의 약제학적으로 허용 가능한 염, 또는 이들의 수화물 또는 용매화물, 이의 제조방법 및 이를 유효량 함유하는 골다공증 완화, 예방 또는 치료용 조성물을 제공한다. [화학식 I]

  本发明提供了以下[化学式I]的新化合物，其药学上可接受的盐，或其水合物或溶剂化合物，以及其制备方法和含有效量的治疗骨质疏松症的缓解、预防或治疗组合物。[化学式I]
• 5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression
  作者：Ju-Hee Kang、Zheng Ting、Mi-ran Moon、Jung-Seon Sim、Jung-Min Lee、Kyung-Eun Doh、Sunhye Hong、Minghua Cui、Sun Choi、Hyeun Wook Chang、Hea-Young Park Choo、Mijung Yim

  DOI：10.1016/j.bmc.2015.09.025

  日期：2015.11

  5-Lipoxygenase synthesizes leukotrienes from arachidonic acid. We developed three novel 5-LO inhibitors having a benzoxazole scaffold as a potential anti-osteoclastogenics. They significantly suppressed RANKL-induced osteoclast formation in mouse bone marrow-derived macrophages. Furthermore, one compound, K7, inhibited the bone resorptive activity of osteoclasts. The anti-osteoclastogenic effect of K7 was mainly attributable to reduction in the expression of NFATc1, an essential transcription factor for osteoclast differentiation. K7 inhibited osteoclast formation via ERR and p38 MAPK, as well as NF-kappa B signaling pathways. K7 reduced lipopolysaccharide (LPS)-induced osteoclast formation in vivo, corroborating the in vitro data. Thus, K7 exerted an inhibitory effect on osteoclast formation in vitro and in vivo, properties that make it a potential candidate for the treatment of bone diseases associated with excessive bone resorption. (C) 2015 Elsevier Ltd. All rights reserved.